


## ASX ANNOUNCEMENT

14 December 2022

# Correction to Announcement and Appendix 3B



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") wishes to correct the following administrative error in its announcement dated 2 November 2022 ("**Announcement**") in respect of its \$4,000,000 placement ("**Placement**") and \$2,000,000 share purchase plan ("**SPP**") and associated Appendix 3B related to the issue of Placement securities ("**Appendix 3B**").

In the Announcement, the Company confirms the paragraph:

*The Placement Securities will be issued within the Company's existing placement capacity under ASX Listing Rules 7.1 (16,122,282 Placement Securities and 20,000,000 Options) and 7.1A (3,877,718 Placement Securities).*

is replaced with:

*The Placement Securities and SPP Options will be issued within the Company's existing placement capacity under ASX Listing Rules 7.1 (20,000,000 Placement Options and up to a further 10,000,000 SPP Options) and 7.1A (20,000,000 Placement Shares).*

The Appendix 3B is also modified to reflect the above corrections and follows this announcement. Capitalised terms in this announcement have the same meaning as in the Announcement.

**ENDS**  
**BY ORDER OF THE BOARD**

A handwritten signature in black ink, appearing to be "Alistair Warren", written over a horizontal line.

**Alistair Warren**  
Company Secretary



For further information please contact:

**Alistair Warren**  
**Company Secretary**

Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +61 8 6280 0050

**Fleta Solomon**  
**Chief Executive Officer**

Little Green Pharma  
E: [f.solomon@lgp.global](mailto:f.solomon@lgp.global)  
T: +61 8 6280 0050

## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m<sup>2</sup> cultivation and 4,000m<sup>2</sup> GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)